Randomized Controlled Trial
Copyright ©The Author(s) 2022.
World J Clin Cases. Jun 6, 2022; 10(16): 5306-5316
Published online Jun 6, 2022. doi: 10.12998/wjcc.v10.i16.5306
Table 3 Changes in outcomes from baseline to 6-mo follow-up (n = 195) [median (IQR)/mean ± SD]
Outcomes
Groups
Assessments, baseline
1 mo
3 mo
6 mo
% of improvement
χ2
P valuea
Significant pairs (posthoc)
Self-esteemExperimental (n = 97)20 (16.50-23); 20.05 ± 4.2222 (18.50-24.50); 21.67 ± 4.0823 (20-26); 22.76 ± 4.2825 (22-28); 24.98 ± 4.3525195.90.001Baseline-1 mo; Baseline-3 mo; Baseline-6 mo; 1-3 mo; 1-6 mo; 3-6 mo
Control (n = 98)19 (17-22); 19.64 ± 3.7320 (17-22); 19.50 ± 3.6720 (17-22); 19.50 ± 3.6720 (17-22); 19.45 ± 4.03524.430.001Baseline-6 mo; 1-6 mo; 3-6 mo; 3-1 mo; 3 mo-Baseline; 1 mo-Baseline
AnxietyExperimental (n = 97)36 (27-41); 34.65 ± 7.8529 (24-39); 30.55 ± 7.5025 (21-32); 26.81 ± 7.6819 (15-26); 21.82 ± 8.5747237.30.0016-3 mo; 6-1 mo; 6 mo-Baseline; 3-1 mo; 3 mo-Baseline; 1 mo-Baseline
Control (n = 98)35 (30-42.5); 36.69 ± 9.3634.50 (29-45); 37.01 ± 10.3331 (26-46); 35.13 ± 11.2328.50 (22-45); 33.02 ± 12.431931.90.0016-3 mo; 6-1 mo; 6 mo-Baseline; 3-1 mo; 3 mo-Baseline; Baseline-1 mo
DepressionExperimental (n = 97)13 (9.50-17); 13.30 ± 5.5612 (9-15); 12.14 ± 5.039 (6-13); 10 ± 5.058 (4-10); 7.58 ± 4.7138243.50.0016-3 mo; 6-1 mo; 6 mo-Baseline; 3-1 mo; 3 mo-Baseline; 1 mo-Baseline
Control (n = 98)12 (9-17); 12.86 ± 5.3410 (7-16); 11.47 ± 5.4410.50 (6-6.25); 11.19 ± 6.3410 (6.75-18); 11.47 ± 6.551748.90.0016 mo-Baseline; 3-1 mo; 3 mo-Baseline; 1 mo-Baseline; 3-6 mo; 1-6 mo